Psych CASC / OSCE · Child and adolescent psychiatry — neurodevelopmental
Explain adult ADHD diagnosis and treatment plan — CASC communication station
MRCPsych/FRANZCP-style communication station: explain adult ADHD formulation, multimodal treatment including medication monitoring, diversion/SUD counselling, and driving advice in plain language.
On this page & tools
Target exams
Station brief
Format. Communication station, approximately 7–10 minutes active time after reading. You are the psychiatry registrar in the adult neurodevelopmental clinic. [2]
Candidate instructions. Explain the working diagnosis of adult ADHD grounded in childhood-onset multi-setting impairment, outline multimodal treatment (skills/accommodations and possible medication), address fears about addiction/diversion, discuss monitoring and driving, and check understanding. The examiner plays the patient; a partner may also be present. [2]
Candidate scenario
Your formulation supports ADHD with predominantly inattentive presentation and residual hyperactive features (inner restlessness), lifelong organisational impairment, and no current manic episode. You are considering a long-acting stimulant after cardiac history screen and baseline vitals, plus CBT/organisational coaching referral. The patient fears becoming "dependent like on painkillers" and asks if medication will make driving illegal. [1][2][5]
Marking domains
- Empathy, structure, agenda-setting (laziness myth, career fears)
- Accurate plain-language explanation of ADHD as neurodevelopmental, not character flaw
- Clear multimodal plan (skills + optional medication) with monitoring
- Honest discussion of stimulant misuse/diversion vs therapeutic use
- Driving counselling without inventing statutes
- Checks understanding and shared decision-making [2][4]
Reveal assessor key
Open and agenda-set. Name time; ask priorities (laziness label, addiction, driving, work). Validate distress without colluding with pure self-blame. [2]
Explain diagnosis. Adult ADHD is a neurodevelopmental condition of attention and self-regulation beginning in childhood; school reports and lifelong multi-setting impairment support it. It is common, impairing, and treatable. It is not the same as occasional stress inattention. Scales helped screening; diagnosis is clinical.[1][2]
Explain treatment. Skills-based approaches and workplace adjustments help; structured CBT/coaching has evidence for residual symptoms. Medication (example long-acting stimulant) can reduce core symptoms for many adults; we check blood pressure/heart rate, sleep, appetite, mood, and safe storage. Benefits of stimulants are often noticed quickly at dose; alternatives like atomoxetine exist if stimulants are unsuitable.[3][5]
Addiction/diversion. Therapeutic use under supervision is different from recreational misuse. We minimise diversion risk with long-acting preparations, limited quantities, and honest review. Alcohol/other drugs worsen function — screen and support. [2]
Driving. Untreated ADHD can increase accident risk; effective treatment and avoiding substances/sleep deprivation support safety. Licensing rules vary by place — we follow local law and document advice rather than inventing bans. [4]
Close. Summarise plan, invite questions, written information, follow-up for titration and skills referral. [2]
References
- [1]Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication Am J Psychiatry, 2006.PMID 16585449
- [2]Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD Eur Psychiatry, 2019.PMID 30453134
- [3]Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial JAMA, 2010.PMID 20736471
- [4]Vaa T ADHD and relative risk of accidents in road traffic: a meta-analysis Accid Anal Prev, 2014.PMID 24238842
- [5]Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis Lancet Psychiatry, 2018.PMID 30097390